Site Language:
Site Language:
Thank you for helping us reach this important study milestone. In recent weeks, our trial sites have been working tirelessly to identify and screen participants, and we appreciate your tremendous effort through the final day of screening. We especially value the patience of sites that have been with us since before the 2023 study pause and commend those who joined this year and immediately began screening. Your ongoing focus and perseverance have been crucial in the study’s success.
Please notify any patients who were previously contacted, screened, or pending re-screening that trial recruitment has now ended. If you have any questions about screening conclusion activities, please reach out to your ProKidney CTL.
As we have previously communicated, the last day to screen a participant was Friday, August 7, 2026, and the last day to randomize will be Friday, November 6, 2026. The end dates for screening and randomization will help ensure that treatment/sham procedures are completed prior to the mid-2027 data readout.
Investigators and participants must remain blinded until the REGEN-006 study closure, projected to occur in the second half of 2029. All randomized participants must be followed, per protocol to ensure they attend their visits and remain in the study until their End-of-Study visit.
Your unwavering commitment to quality trial execution and patient care has been essential to the study’s progress, and we look forward to your continued partnership as we work toward study completion in 2029.
In the Clinical Study Report, we will summarize the number of participants who experience each type of adverse event (AE). To ensure consistent AE terminology across study sites and enable accurate analysis of similar events, AE terms entered by sites are standardized using the MedDRA dictionary.
As part of this process, you may receive queries regarding AE terminology to help ensure events are coded, standardized, and counted appropriately. Common queries may include:
Additionally, CTCAE grading is used to standardize reporting of event severity. The full CTCAE dictionary is available online. In general, CTCAE grades are defined according to the descriptions below. If an event term and/or interventions given (or not given) do not appear consistent with the assigned CTCAE grade, you may receive a query.
Click here to visit the CTCAE Dictionary
Source documents for adjudication must be collected and submitted through the WCG AIMS Portal. Over 20 sites currently have outstanding uploads. Timely submission is critical, so endpoint adjudication can proceed as required by the protocol. Please ensure that you upload any outstanding source ASAP.
Need help? AIMS portal issues: see the AIMS external user guide on Longboat or contact aimssupport@wcgclinical.com
Questions on the adjudication process: reach out to your PSI CRA and copy Marci.Parks@prokidney.com
Here’s information we’ve gathered to help you make the best decision for your health journey.
Guidance on End of Treatment
As we progress through the study, please remember that participants who do not complete all procedures should continue their study participation. This helps us capture important safety and efficacy data. Additionally, participants reaching transplant, dialysis, or specific kidney function milestones have abbreviated follow-up schedules. If you have any questions, please contact your PSI CRA or Medical Monitor.
End of Treatment (EOT)
Reasons End of Treatment in EDC:
End of Study (EOS)